Glycated hemoglobin News and Research

RSS

Tubing-Free Insulin Pump System improves glycemic control in diabetic patients

Albany College of Pharmacy and Health Sciences and The Endocrine Group researchers have concluded that the OmniPod® Insulin Management System significantly improved blood glucose control in diabetes patients who previously received insulin through multiple daily injections. The retrospective study results were published in the latest issue of Infusystems USA, in a study titled, 'Clinical Experience with a Tubing-Free Insulin Pump System.'

2 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

Lexicon Pharmaceuticals reports positive results from its LX4211 Phase 2 trial in type 2 diabetic patients

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load.

20 Jan 2010

Evidence suggests insulin pumps may help in maintaining blood glucose levels in type 1 diabetic patients

A new evidence review suggests that using a pump to deliver insulin continuously — instead of taking three or more daily injections — might result in better control of blood sugar for people with type 1 diabetes.

18 Jan 2010

OSA adversely affects glucose control in patients with type 2 diabetes

Obstructive Sleep Apnea (OSA) adversely affects glucose control in patients with type 2 diabetes, according to a study conducted by researchers at the University of Chicago.

18 Jan 2010

American Clinical Laboratory Association lauds ADA's recommendation of HbA1C test for diabetes

The American Clinical Laboratory Association's Results for Life Campaign today applauded the American Diabetes Association for its decision to recommend the hemoglobin A1C laboratory test as a means of diagnosing diabetes and identifying pre-diabetes.

9 Jan 2010

Non-insulin-dependent patients with type 2 diabetes do not benefit from glucose self-monitoring

Contrary to the widely-held belief, there is no proof that non-insulin-dependent patients with type 2 diabetes benefit from glucose self-monitoring. Moreover, it remains unclear whether an additional benefit is displayed by the blood test compared to the urine test or vice versa, in other words, whether one or other of the tests might offer an advantage to patients.

8 Jan 2010

Patient enrollment in Tolerx's Phase 3 clinical study DEFEND-1 completed

Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.

8 Jan 2010

Headline results from first phase III study of Balaglitazone announced

Dr. Reddy’s Laboratories Ltd. and Rheoscience, a subsidiary of Nordic Bioscience A/S, today announced the headline results from the first phase III study for their investigational agent, Balaglitazone.

4 Jan 2010

ADA recommends the A1C test for diabetes screening and diagnosis

New official guidelines for diabetes screening and diagnosis now include a blood test that gives a person's average blood glucose level over the previous 2-3 months.

30 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

Physicians favor agents that can reduce HbA1c levels by 2% in diabetes patients

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that over 70 percent of surveyed U.S. physicians indicate there is a high need for diabetes drugs with novel mechanisms of action versus 15 percent who say there is a high need for additional DPP-IV inhibitors.

18 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Fourth-quarter and full year fiscal 2009 results announced by Biodel

Biodel Inc. today reported financial results for the fourth quarter and fiscal year ended September 30, 2009.

10 Dec 2009

Despite rising costs of U.S. health care, quality lags in ambulatory care

Most primary care physicians active in the Medicare program work in practices with too few patients to reliably measure significant differences in common measures of quality and cost performance, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Majority of Canadians living with diabetes do not receive all clinical tests from health providers

While most Canadian adults living with diabetes get regular care, they are not always getting all of the clinically recommended tests they require to prevent health complications.

4 Dec 2009

Report on the type 2 diabetes drug market in Brazil

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

3 Dec 2009

Roche announces results of phase III taspoglutide study in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed the results of the second and third of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first human once weekly glucagon-like peptide-1 (GLP-1) analogue originating from Ipsen’s research and developed by Roche.

2 Dec 2009

GI Dynamics to present interim data on its EndoBarrier Gastrointestinal Liner study

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that interim data from its ongoing clinical study of the EndoBarrier™ Gastrointestinal Liner in obese patients with type 2 diabetes will be presented by Eduardo G. Moura, M.D., Ph.D., director of endoscopy, digestive surgery department, Hospital das Clinicas, University of Sao Paulo, on Monday, November 23, 2009 at GASTRO 2009.

23 Nov 2009